Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631744 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04631744 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 4 participants.
The verdict
NCT04631744, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2025-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04631744
The ClinicalTrials.gov registry entry for NCT04631744 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT04631744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04631744 about?
NCT04631744 is a clinical study titled "Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)". The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRP...
What is the current status of trial NCT04631744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-03-03. Estimated completion is 2025-11-09.
What interventions are being tested in trial NCT04631744?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04631744?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.